DMS Imaging

Equities

DMSIM

BE0974289218

Healthcare Facilities & Services

Market Closed - Euronext Bruxelles Other stock markets 07:20:19 2024-04-29 am EDT			5-day change	1st Jan Change
0.018 ^EUR	0.00%		-13.46%	-23.40%

2023	DMS Imaging SA Reports Earnings Results for the Half Year Ended June 30, 2023	CI
2023	DMS Imaging SA Reports Earnings Results for the Full Year Ended December 31, 2022	CI

ASIT Biotech S.A. Reports Earnings Results for the Full Year Ended December 31, 2018

April 02, 2019 at 03:00 am EDT

ASIT Biotech S.A. announced earnings results for the full year ended December 31, 2018. For the full year, the company announced operating loss was EUR 12.767 million compared to EUR 11.976 million a year ago. Net loss was EUR 14.321 million compared to EUR 11.986 million a year ago.

Latest news about DMS Imaging

DMS Imaging SA Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-21	CI
DMS Imaging SA Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-28	CI
Diagnostic Medical Systems Unit Receives Order for Radiology Tables in Italy	23-01-12	MT
DMS Imaging SA Reports Earnings Results for the Half Year Ended June 30, 2022	22-09-30	CI
DMS Imaging SA Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-30	CI
Diagnostic Medical Systems Takes Majority Stake In Asit Biotech	22-01-25	MT
Global markets live: Microsoft, Apple, The Boeing Company, AT&T, Activision Blizzard...	21-09-15
Asit Biotech S.A. Reports Earnings Results for the Half Year Ended June 30, 2020	20-09-30	CI
GLOBAL MARKETS LIVE: UBS eying new acquisition, Deutsche Bank’s suspicious transactions…	20-09-21
Asit Biotech S.A. Reports Earnings Results for the Full Year Ended December 31, 2019	20-05-06	CI
ASIT Biotech S.A. Announces Board Changes	20-01-20	CI
ASIT biotech Discloses Next Steps Following gp-ASIT+TM Phase III Results	19-12-20	CI
ASIT Biotech gp-ASIT+™ Phase III Trial in Grass Pollen Allergy Did Not Meet the Primary Endpoint	19-11-25	CI
ASIT Biotech Announces the Publication of a Mechanistic Study of Gp-ASIT+™, its Lead Product Candidate in Phase III	19-10-17	CI
ASIT Biotech Receives GMP Certification for Its Manufacturing Site in Liège, Belgium	19-10-07	CI
Biotech Tools Sa Reports Earnings Results for the Half Year Ended June 30, 2019	19-09-18	CI
ASIT biotech Confirms on Track for Phase III Results of gp-ASIT+™ in December 2019	19-09-05	CI
ASIT Biotech Raises EUR 9.225 Million in A Private Placement of Convertible Notes	19-07-22	CI
ASIT Biotech S.A. announced that it has received €9.225 million in funding	19-07-21	CI
ASIT Biotech S.A. announced a financing transaction	19-06-27	CI
ASIT Biotech Announces the Achievement of New Clinical and Corporate Development Milestones	19-05-02	CI
ASIT Biotech Appoints Frank Hazevoets as Chief Financial Officer	19-05-02	CI
ASIT Biotech S.A. Reports Earnings Results for the Full Year Ended December 31, 2018	19-04-02	CI
ASIT Biotech S.A. Provides Clinical Update	19-04-02	CI
ASIT Biotech S.A. Reveals the Mode of Action of its Immunotherapy Product for Allergic Rhinitis, gp-ASIT+™, in the Journal of Allergy and Clinical Immunology	19-03-05	CI

Chart DMS Imaging

Duration

Period

More charts

Company Profile

DMS Imaging specializes in the design and manufacture of imaging systems for digital and conventional radiology and bone densitometry. DMS Imaging offers radiology equipment (mobile radiology units, floating panel tables, mobile C-arm for operating room, etc.), ultrasound bone densitometers (for the reconstruction of bone microarchitecture), X-ray bone densitometers (for the measurement of bone density), etc. Net sales are distributed geographically as follows: Europe (61.3%), North and South America (18.4%), Asia (7.1%), Middle East (4.5%), Africa (3 .9%), Oceania (1.1%) and other (3.7%).

Sector

Healthcare Facilities & Services

Calendar

2024-09-17 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Medical & Diagnostic Laboratories

	1st Jan change	Capi.
DMS IMAGING	-23.40%	28.62M
SONIC HEALTHCARE LIMITED	-16.58%	8.25B
RADNET, INC.	+41.06%	3.58B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-35.59%	2.46B
SYNLAB AG	-7.88%	2.46B
DR. LAL PATHLABS LIMITED	-8.95%	2.38B
NEOGENOMICS, INC.	-5.19%	1.81B
FLEURY S.A.	-19.24%	1.55B
DIAN DIAGNOSTICS GROUP CO.,LTD.	-38.35%	1.21B
METROPOLIS HEALTHCARE LIMITED	+6.91%	1.11B

Medical & Diagnostic Laboratories